Significance of p53 Immunoreactivity in Squamous Cell Carcinoma of the Cervix Treated with Radiotherapy Alone.
- Author:
Sung Ja AHN
1
;
Ho Sun CHOI
;
Chan CHOI
;
Byung Sik NAH
;
Woong Ki CHUNG
;
Taek Keun NAM
Author Information
1. Department of Therapeutic Radiology, Chonnam University Medical School, Gwang-ju, Korea.
- Publication Type:Original Article
- Keywords:
Cervix neoplasm;
p53;
Tumor behavior;
Radiotherapy
- MeSH:
Brachytherapy;
Carcinoma, Squamous Cell*;
Cervix Uteri*;
Female;
Follow-Up Studies;
Humans;
Jeollanam-do;
Multivariate Analysis;
Radiation Oncology;
Radiotherapy*;
Treatment Failure;
Ulcer;
Uterine Cervical Neoplasms
- From:Journal of the Korean Cancer Association
2001;33(2):106-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We undertook this study to evaluate the significance of p53 immunoreactivity in squamous cell carcinoma of the cervix, treated with radiotherapy alone. MATERIALS AND METHODS: Immunohistochemical staining of p53 proteins were performed in eighty patients with squamous cell carcinoma of the cervix, and who completed curative radiotherapy between Jan. 1996 and Apr. 1998 at the Department of Therapeutic Radiology, Chonnam National University Hospital. External- beam radiotherapy was combined with intracavitary brachytherapy. Results were analyzed for the end points of pelvic tumor control and distant failure rates. The follow-up time ranged from 7 to 58 months with a median of 40 months. RESULTS: p53 positive and negative groups involved 45 and 35 patients, respectively, and the positive p53 immunoreactivity rate was 56% (45/80). p53 immunoreactivity showed no significant correlation with age, tumor size, serum tumor marker (SCC), or HPV18 expression, while there was a statistically marginally significant correlation with HPV16 expression. The pelvic tumor control rate of the p53 positive group was 87% and that of p53 negative group was 83% (0.05). The other parameters influencing negatively to the pelvic tumor control and with statistical significance were tumor ulceration and barrel type. Multivariate analysis also showed that p53 immunoreactivity had no prognostic value for pelvic tumor control of the disease, and that the statistically significant factor was tumor ulceration. The treatment failure rate of the p53 positive group was 23% and that of the negative group was 26% (p>0.05). CONCLUSION: p53 immunoreactivity in the cervix cancer stage IB, II patients seems to have no value as a predictor of tumor behavior after curative radiotherapy.
